Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model

Journal of Vascular Surgery

Volumn 39, Issue 6, 2004, Pages 1322-1328

  Lin, Peter H ^a,b,d   Chen, Changyi ^a,b   Bush, Ruth L ^a,b   Yao, Qizhi ^a,b   Lumsden, Alan B ^a,b   Hanson, Stephen R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

^d Oregon Hlth S ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; POLITEF;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS SHUNT; ARTERY GRAFT; ARTICLE; BABOON; BYPASS SURGERY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMORAL ARTERY; FEMORAL VEIN; GRAFT FAILURE; GRAFT PATENCY; HYPERPLASIA; ILIAC ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS; SCINTILLATION CAMERA; THROMBOCYTE; THROMBOSIS;

EID: 3242701663     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2004.01.046     Document Type: Article

References (39)

1. Sayers R.D., Raptis S., Berce M., Miller J.H. Long-term results of femorotibial bypass with vein or polytetrafluoroethylene. Br J Surg. 85:1998;934-938
2. Brewster D.C., LaSalle A.J., Robison J.G., Strayhorn E.C., Darling R.C. Factors affecting patency of femoropopliteal bypass grafts. Surg Gynecol Obstet. 157:1983;437-442
3. Guyton J.R., Rosenberg R.D., Clowes A.W., Karnovsky M.J. Inhibition of rat arterial smooth muscle cell proliferation by heparin in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 46:1980;625-634
4. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:1977;625-626
5. Letourneur D., Caleb B.L., Castellot J.J. Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells. I Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol. 165:1995;676-686
6. Clowes A.W., Reidy M.A., Clowes M.M. Mechanisms of stenosis after arterial injury. Lab Invest. 49:1983;208-215
7. Clowes A.W., Clowes M.M., Kirkman T.R., Jackson C.L., Au Y.P., Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res. 70:1992;1128-1136
8. Chen C., Lumsden A.B., Hanson S.R. Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons. J Vasc Surg. 31:2000;354-363
9. Lin P.H., Chronos N.A., Marijianowski M.M., Chen C., Conklin B., Bush R.L., et al. Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model. J Surg Res. 112:2003;84-90
10. Lin P.H., Chronos N.A., Marijianowski M.M., Chen C., Bush R.L., Lumsden A.B., et al. Heparin-coated balloon-expandable stent reduces intimal hyperplasia in the iliac artery in baboons. J Vasc Interv Radiol. 14:2003;603-611
11. Sanchez J., Elgue G., Riesenfeld J., Olsson P. Control of contact activation on end-point immobilized heparin the role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res. 29:1995;655-661
12. Riesenfeld J., Olsson P., Sanchez J., Mollnes T.E. Surface modification with functionally active heparin. Med Device Technol. 6:1995;24-31
13. Giese N.A., Marijianowski M.M., McCook O., Hancock A., Ramakrishnan V., Fretto L.J., et al. The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler Thromb Vasc Biol. 19:1999;900-909
14. Chen C., Ofenloch J.C., Yianni Y.P., Hanson S.R., Lumsden A.B. Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts. J Surg Res. 77:1998;119-125
15. Hanson S.R., Powell J.S., Dodson T., Lumsden A., Kelly A.B., Anderson J.S., et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 18:1991;II70-76
16. Chen C., Mattar S.G., Hughes J.D., Pierce G.F., Cook J.E., Ku D.N., et al. Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. Circulation. 94:1996;1989-1995
17. Jackson M.R., Belott T.P., Dickason T., Kaiser W.J., Modrall J.G., Valentine R.J., et al. The consequences of a failed femoropopliteal bypass grafting comparison of saphenous vein and PTFE grafts. J Vasc Surg. 32:2000;498-504
18. Nolan K.D., Benjamin M.E., Murphy T.J., Pearce W.H., McCarthy W.J., Yao J.S., et al. Femorofemoral bypass for aortofemoral graft limb occlusion a ten-year experience. J Vasc Surg. 19:1994;851-856. discussion 856-7
19. Weyand M., Kerber S., Schmid C., Rolf N., Scheld H.H. Coronary artery bypass grafting with an expanded polytetrafluoroethylene graft. Ann Thorac Surg. 67:1999;1240-1244. discussion 1244-5
20. Biancari F., Railo M., Lundin J., Alback A., Kantonen I., Lehtola A., et al. Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia. Eur J Vasc Endovasc Surg. 21:2001;137-142
21. Eagleton M.J., Ouriel K., Shortell C., Green R.M. Femoral-infrapopliteal bypass with prosthetic grafts. Surgery. 126:1999;759-764. discussion 764-5
22. Ferguson J.J., Waly H.M., Wilson J.M. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J. 135:(suppl):1998;S35-42
23. Tayama E., Hayashida N., Akasu K., Kosuga T., Fukunaga S., Akashi S., et al. Biocompatibility of heparin-coated extracorporeal bypass circuits new heparin bonded bioline system. Artif Organs. 24:2000;618-623
24. Dewanjee M.K., Palatianos G.N., Kapadvanjwala M., Hsu L.C., Novak S., Balantino G., et al. Neutrophil dynamics and retention in lung, oxygenator, and arterial filter during cardiopulmonary bypass in a pig model. ASAIO Trans. 40:1994;M547-553
25. Serruys P.W., Emanuelsson H., van der Giessen W., Lunn A.C., Kiemeney F., Macaya C., et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries early outcome of the Benestent-II Pilot Study. Circulation. 93:1996;412-422
26. Fager G., Camejo G., Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin. In Vitro Cell Dev Biol. 28A:1992;168-175
27. Au Y.P., Kenagy R.D., Clowes M.M., Clowes A.W. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 23:(suppl 1):1993;177-182
28. Reilly C.F., Kindy M.S., Brown K.E., Rosenberg R.D., Sonenshein G.E. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem. 264:1989;6990-6995
29. Castellot J.J. Jr, Wong K., Herman B., Hoover R.L., Albertini D.F., Kaisee W.J., et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol. 124:1985;13-20
30. Ottlinger M.E., Pukac L.A., Karnovsky M.J. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J Biol Chem. 268:1993;19173-19176
31. Herbert J.M., Clowes M., Lea H.J., Pascal M., Clowes A.W. Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J Biol Chem. 271:1996;25928-25935
32. Au Y.P., Dobrowolska G., Morris D.R., Clowes A.W. Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ Res. 75:1994;15-22
33. Nugent M.A., Karnovsky M.J., Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res. 73:1993;1051-1060
34. Reilly C.F., Fritze L.M., Rosenberg R.D. Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor. J Cell Physiol. 131:1987;149-157
35. McCaffrey T.A., Falcone D.J., Brayton C.F., Agarwal L.A., Welt F.G., Weksler B.B. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol. 109:1989;441-448
36. Au Y.P., Montgomery K.F., Clowes A.W. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells. Circ Res. 70:1992;1062-1069
37. Faxon D.P., Spiro T.E., Minor S., Cote G., Douglas J., Gottlieb R., et al. Low molecular weight heparin in prevention of restenosis after angioplasty results of Enoxaparin Restenosis (ERA) Trial. Circulation. 90:1994;908-914
38. Laskey M.A., Deutsch E., Hirshfeld J.W. Jr, Kussmaul W.G., Barnathan E., Laskey W.K. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol. 65:1990;179-182
39. Au Y.P., Kenagy R.D., Clowes A.W. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem. 267:1992;3438-3444